Tarveda Therapeutics Provides Update on Proposed Merger with Organovo

WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, today announced that the proposed merger agreement with Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) has been terminated following the emergence of unanticipated, late opposition to the proposed transaction by major Organovo stockholders.